LARTRUVO

This brand name is authorized in United States. It is also authorized in Brazil, Estonia, Ireland, Lithuania, Poland.

Active ingredients

The drug LARTRUVO contains one active pharmaceutical ingredient (API):

1	Olaratumab UNII TT6HN20MVF - OLARATUMAB
	Olaratumab is an antagonist of platelet derived growth factor receptor-α (PDGFR-α), expressed on tumour and stromal cells. Olaratumab is a targeted, recombinant, fully human immunoglobulin G subclass 1 (IgG1) monoclonal antibody that specifically binds PDGFR-α, blocking PDGF AA, -BB, and CC binding and receptor activation. As a result, in vitro olaratumab inhibits PDGFRα pathway signalling in tumour and stromal cells. In addition, in vivo olaratumab has been shown to disrupt the PDGFR-α pathway in tumour cells and inhibit tumour growth.
	Read more about Olaratumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LARTRUVO Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX10	Olaratumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	507618030021401
EE	Ravimiamet	1732766, 1753668, 1753679
LT	Valstybinė vaistų kontrolės tarnyba	1081608, 1084355, 1084356
PL	Rejestru Produktów Leczniczych	100381944
US	FDA, National Drug Code	0002-7190, 0002-8926